Will This Potential Approval Be a Winner for Sanofi's Shareholders?

Will This Potential Approval Be a Winner for Sanofi's Shareholders?

Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.